EC
HAE icon

Eminence Capital’s Haemonetics HAE Stock Holding History

Eminence Capital’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-847,328
Closed -$84.4M – 92
2020
Q1 		$84.4M Buy
847,328
+557,188
+192% +$60.4M 0.92% 39
2019
Q4 		$33.3M Sell
290,140
-8,566
-3% -$1.04M 0.37% 53
2019
Q3 		$37.7M Sell
298,706
-581,513
-66% -$73.8M 0.45% 52
2019
Q2 		$106M Buy
880,219
+768,863
+690% +$75.6M 1.4% 29
2019
Q1 		$9.74M Buy
+111,356
New +$10.1M 0.15% 42

Other funds holding HAE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital's HAE Position: Q2 2020 in Review

Eminence Capital sold out of Haemonetics (HAE) in Q2 2020, closing a stake of 847,328 shares — an estimated $84.4M sold.

Eminence Capital first reported a position in HAE in Q1 2019 and held it in 5 quarters. The position peaked at $106M in Q2 2019. 285 funds tracked by Wall St. Rank hold HAE as of Q2 2020.

  • Eminence Capital reported no remaining Haemonetics position as of Q2 2020 after selling out during the quarter.
  • Eminence Capital sold 847,328 Haemonetics shares in Q2 2020, an estimated $84.4M.
  • Eminence Capital first reported a position in Haemonetics in Q1 2019 and held it in 5 quarters.
  • Eminence Capital's Haemonetics position peaked at $106M in Q2 2019.
  • 285 funds tracked by Wall St. Rank held Haemonetics as of Q2 2020.

Based on Eminence Capital's 13F filing for Q2 2020, filed 17 Aug 2020.